Nutrition in Cancer and Hematologic Disease
Nutrition in cancer and hematologic disease is the area of clinical nutrition concerned with assessing and supporting the nutritional status of people with malignant solid tumours and blood cancers, both during active anticancer treatment and across survivorship. It addresses the dual burden of the tumour's own metabolic effects and the nutritional toxicity of chemotherapy, radiotherapy, surgery, and stem-cell transplantation.
Definition
Nutrition in cancer and hematologic disease is the branch of clinical nutrition that studies how cancer and its therapies alter intake, absorption, and metabolism, and how nutritional assessment and support are integrated into oncologic and hematologic care.
Scope
The area orients the reader to why malignancy and its treatments threaten nutritional status, and to the major syndromes that clinical nutrition addresses in oncology and hemato-oncology: cancer cachexia and wasting, treatment-related toxicities affecting intake, the intensive setting of hematopoietic stem cell transplantation, mucositis and swallowing disorders, and graft-versus-host disease. It is a reference overview that frames its child topics rather than providing individualized treatment plans.
Sub-topics
Core questions
- How do tumour-driven metabolism and treatment toxicity each contribute to weight loss and malnutrition in cancer?
- When does nutritional support belong in the oncology and transplant care pathway?
- How are the distinct syndromes of cachexia, mucositis, and graft-versus-host disease distinguished and addressed nutritionally?
Key concepts
- Cancer-related malnutrition
- Cancer cachexia
- Nutritional screening and assessment in oncology
- Treatment-related nutritional toxicity
- Hematopoietic stem cell transplantation
- Survivorship nutrition
Mechanisms
Two broad mechanisms converge to undermine nutritional status in cancer. First, the tumour and the host inflammatory response drive a catabolic metabolic state with anorexia, altered substrate handling, and loss of skeletal muscle, the core of cancer cachexia. Second, anticancer treatments impair intake and absorption directly: nausea, mucositis, dysgeusia, dysphagia, malabsorption, and the organ injury of high-dose conditioning and graft-versus-host disease. Clinical nutrition in this area therefore combines screening and assessment with mechanism-specific support, recognizing that reversing intake deficits alone does not fully reverse cachexia.
Clinical relevance
Malnutrition is common across cancer types and is associated with poorer tolerance of treatment, reduced quality of life, and worse outcomes, which is why nutritional screening and support are embedded in modern oncology and transplant guidelines. This area describes how nutrition is integrated into cancer care as a reference for learners; it is not a substitute for the individualized assessment and prescribing performed by the treating multidisciplinary team.
Epidemiology
Cancer is among the leading causes of disease burden worldwide, and the population of people living during and after treatment continues to grow, increasing the relevance of supportive and survivorship nutrition. Weight loss and malnutrition affect a substantial fraction of patients, with the highest frequencies in upper gastrointestinal, head and neck, and advanced disease, and in the intensive setting of stem-cell transplantation.
Evidence & guidelines
Major guidance for this area is provided by the European Society for Clinical Nutrition and Metabolism (ESPEN) guidelines on nutrition in cancer patients (Arends et al., 2017) and the corresponding ESPEN practical guideline (Muscaritoli et al., 2021), which cover screening, assessment, and the use of oral, enteral, and parenteral support. The international consensus definition of cancer cachexia (Fearon et al., 2011) underpins how wasting is classified across the area.
Key figures
- Jann Arends
- Maurizio Muscaritoli
- Kenneth Fearon
- Vickie Baracos
Related topics
Seminal works
- arends-2017-espen
- fearon-2011-consensus
- muscaritoli-2021-espen
Frequently asked questions
- Why is nutrition a distinct concern in cancer rather than just a general health issue?
- Cancer combines a catabolic, inflammation-driven metabolic state with treatment toxicities that impair eating and absorption, so malnutrition can develop even in patients who were previously well-nourished and can affect how treatment is tolerated.
- Does this area include blood cancers as well as solid tumours?
- Yes. It covers both solid malignancies and hematologic disease, including the intensive nutritional setting of hematopoietic stem cell transplantation and its complications such as graft-versus-host disease.